Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Preimplantation genetic diagnosis is used to test aneuploidy in the cases of low prognosis in patients opting for in vitro fertilization. It is also instrumental in detection of hereditary single gene disorders, X linked diseases and recently, also for diagnosis of late onset diseases.

Statistics:

The global preimplantation genetic diagnosis market is estimated to account for US$ 53.5 Mn in terms of value in 2020 and is expected to reach US$ 81.6 Mn by the end of 2027.

Global Preimplantation Genetic Diagnosis Market: Drivers

Increasing incidences of genetic diseases is expected to propel growth of the global preimplantation genetic diagnosis market over the forecast period. For instance, according to the study, ‘Estimating Nationwide Prevalence of Live Births with Down Syndrome and Their Medical Expenditures in Korea’, published in Journal of Korean Medical Science in August 2019, the prevalence of live births with Down’s syndrome was 5.03 per 10,000 births between 2007 and 2016.

Moreover, increasing number of fertility centers is also expected to aid in growth of the global preimplantation genetic diagnosis market. For instance, in November 2018, Oregon Reproductive Medicine, a fertility center, started its new clinic in Tigard, Oregon called ORM South.

Statistics:

Chromosomal Abnormalities held dominant position in the global preimplantation genetic diagnosis market in 2019, accounting for 20.1% share in terms of value, followed by X-linked diseases and Aneuploidy, respectively.

Figure 1. Global Preimplantation Genetic Diagnosis Market Share (%), by Value, by Type, 2019

Preimplantation Genetic Diagnosis  | Coherent Market Insights

Global Preimplantation Genetic Diagnosis Market: Restraints

Non-availability of embryos for transfer is expected to hinder growth of the global preimplantation genetic diagnosis market. In almost one third of couples opting for preimplantation genetic diagnosis cycles, the result is that there is absence of normal transferrable embryos. This could be owing to the reason that sometimes women may show poor response to the given ovarian stimulation and as a result lesser eggs are produces. In other cases, despite there is an availability of a fair quantity of embryos, their chromosomal value is found to be consistently abnormal.

Moreover, couples who fail in previous IVF of preimplantation genetic diagnosis cycles have very low chances of future success. Such disadvantages further holdback growth of the global preimplantation genetic diagnosis market.

request-sample

Preimplantation Genetic Diagnosis Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 53.5 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.2% 2027 Value Projection: US$ 81.6 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Type: Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single gene disorders, HLA Typing, Gender Selection, Others (for disability, adult onset disease).
  • By End User: Diagnostic Laboratories, Hospitals, Clinics.
Companies covered:

Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., and Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.

Growth Drivers:
  • Increasing incidences of genetic diseases
  • Increasing number of fertility centers
Restraints & Challenges:
  • Non-availability of embryos for transfer

Global Preimplantation Genetic Diagnosis Market: Opportunities 

Application of preimplantation genetic diagnosis in the field of oncology is expected to offer lucrative growth opportunities for players in the global preimplantation genetic diagnosis market. Preimplantation genetic diagnosis has the potential of reducing the chances of conceiving a cancer affected pregnancy. It can help in determination of the gender of the embryo and further only the genetically fit embryos will be implanted and a healthy pregnancy can thus be conceived.

Moreover, further development in DNA technology will improve accuracy in preimplantation genetic diagnosis, thereby aiding in growth of the market.

The global preimplantation genetic diagnosis market was valued at US$ 50.3 Mn in 2019 and is forecast to reach a value of US$ 81.6 Mn by 2027 at a CAGR of 6.2% between 2020 and 2027.

Figure 2. Global Preimplantation Genetic Diagnosis Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Preimplantation Genetic Diagnosis  | Coherent Market Insights

Market Trends/Key Takeaways

Major players in the global preimplantation genetic diagnosis market are focused on launching new products to expand their product portfolio. For instance, in December 2018, Agilent Technologies Inc. introduced OnePGT, a genome-wide, next-generation sequencing (NGS) solution for preimplantation genetic testing.        

Moreover, increasing network of fertility centers is expected to aid in growth of the global preimplantation genetic diagnosis market. For instance, in October 2018, Prelude Fertility partnered with NYU Langone Health to establish NYU Langone Fertility Center (Fertility Center).

Global Preimplantation Genetic Diagnosis Market: Competitive Landscape

Major players operating in the global preimplantation genetic diagnosis include, Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.

Global Preimplantation Genetic Diagnosis Market: Key Developments

Major players in the global preimplantation genetic diagnosis market are focused on adopting partnership and collaboration strategies to enhance their market share. For instance, in July 2020, Thermo Fisher Scientific partnered with First Genetics JCS, a manufacturer of diagnostic equipment and IVD kits intended to advance molecular genetic technologies into clinical practice, for commercialization of next-generation sequencing (NGS)–based diagnostics in Russia.

Preimplantation genetic diagnosis (PGD) is the genetic profiling of the pre implantable embryos and oocytes before their implantation. The preimplantation genetic diagnosis is similar to that of the parental diagnosis in case of screening for a particular genetic disease. The PGD is advantageous in a way that helps to avoid selective pregnancy termination by the development and growth of the healthy fetus. PGD serves as an addendum to assisted reproductive technology. The preimplantation genetic diagnosis is required in vitro fertilization, in order to obtain oocytes from the embryos for the genetic evaluation of the diseased or disease-free conditions. In simpler terms, the preimplantation genetic diagnosis is a technique that is used to identify embryos at risk.

Restraints of the Global Preimplantation Genetic Diagnosis Market

Major factors hampering the growth of the preimplantation genetic diagnosis market during the forecast period constitutes of non-availability of embryos for transfer.

Key features of the study:

  • This report provides in-depth analysis of the global preimplantation genetic diagnosis market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global preimplantation genetic diagnosis market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global preimplantation genetic diagnosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Preimplantation Genetic Diagnosis Market, By Type:
    • Chromosomal Abnormalities
    • Aneuploidy
    • X-linked diseases
    • Single gene disorders
    • HLA Typing
    • Gender Selection
    • Others (for disability, adult onset disease)
  • Global Preimplantation Genetic Diagnosis Market, By End User:
    • Diagnostic Laboratories
    • Hospitals
    • Clinics
  • Global Preimplantation Genetic Diagnosis Market, By Geography:
    • North America
      • By Type
        • Chromosomal Abnormalities
        • Aneuploidy
        • X-linked diseases
        • Single gene disorders
        • HLA Typing
        • Gender Selection
        • Others (for disability, adult onset disease)
      • By End User
        • Diagnostic Laboratories
        • Hospitals
        • Clinics
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Type
        • Chromosomal Abnormalities
        • Aneuploidy
        • X-linked diseases
        • Single gene disorders
        • HLA Typing
        • Gender Selection
        • Others (for disability, adult onset disease)
      • By End User
        • Diagnostic Laboratories
        • Hospitals
        • Clinics
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type
        • Chromosomal Abnormalities
        • Aneuploidy
        • X-linked diseases
        • Single gene disorders
        • HLA Typing
        • Gender Selection
        • Others (for disability, adult onset disease)
      • By End User
        • Diagnostic Laboratories
        • Hospitals
        • Clinics
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Type
        • Chromosomal Abnormalities
        • Aneuploidy
        • X-linked diseases
        • Single gene disorders
        • HLA Typing
        • Gender Selection
        • Others (for disability, adult onset disease)
      • By End User
        • Diagnostic Laboratories
        • Hospitals
        • Clinics
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Type
        • Chromosomal Abnormalities
        • Aneuploidy
        • X-linked diseases
        • Single gene disorders
        • HLA Typing
        • Gender Selection
        • Others (for disability, adult onset disease)
      • By End User
        • Diagnostic Laboratories
        • Hospitals
        • Clinics
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type
        • Chromosomal Abnormalities
        • Aneuploidy
        • X-linked diseases
        • Single gene disorders
        • HLA Typing
        • Gender Selection
        • Others (for disability, adult onset disease)
      • By End User
        • Diagnostic Laboratories
        • Hospitals
        • Clinics
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Amgen Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Quest Diagnostics
    • Vertex
    • PerkinElmer, Inc.
    • F. Hoffman-La-Roche Ltd
    • Thermo Fisher Scientific, Inc.
    • Laboratory Corporation of America Holdings
    • Abbott Laboratories
    • Illumina, Inc.
    • Natera Inc.
    • CooperGenomics Inc.
    • Reproductive Genetics Institute, Inc.
    • Genea Ltd.
    • Invitae Corporation
    • CombiMatrix Corporation

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By End User
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis
  4. Global Preimplantation Genetic Diagnosis Market, By Type, 2016 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Chromosomal Abnormalities
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Aneuploidy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • X-linked diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Single gene disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • HLA Typing
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Gender Selection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Others (for disability, adult onset disease)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Preimplantation Genetic Diagnosis Market, By End User, 2016 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Diagnostic Laboratories
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Preimplantation Genetic Diagnosis Market, By Regions, 2016 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • Amgen Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Quest Diagnostics
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Vertex
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • PerkinElmer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffman-La-Roche Ltd
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Thermo Fisher Scientific, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Laboratory Corporation of America Holdings
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Illumina, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Natera Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • CooperGenomics Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Reproductive Genetics Institute, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Genea Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Invitae Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • CombiMatrix Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 34 market data tables and 25 figures on “Preimplantation Genetic Diagnosis Market – Global forecast to 2027.

Frequently Asked Questions

The global preimplantation genetic diagnosis market was valued at US$ 50.3 Mn in 2019 and is forecast to reach a value of US$ 81.6 Mn by 2027 at a CAGR of 6.2% between 2020 and 2027.
Major factor driving the growth of global preimplantation genetic diagnosis market during the forecast period include increasing incidences of genetic diseases, and increasing number of fertility centers.
Major factors hampering the growth of the preimplantation genetic diagnosis market during the forecast period constitutes of non-availability of embryos for transfer.
Chromosomal abnormalities held dominant position in the global preimplantation genetic diagnosis market in 2019.
North America Preimplantation Genetic Diagnosis market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., and Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner